Selected research
Industry Growth & Trends
Global In Vivo Pharmacology Service Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global In Vivo Pharmacology Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for In Vivo Pharmacology Service is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for In Vivo Pharmacology Service is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for In Vivo Pharmacology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the In Vivo Pharmacology Service market include NuChem Sciences Inc, Eurofins Discovery, Oncodesign Services, Jubilant Biosys, Pharmaron, Melior Discovery, NUVISAN GmbH, Porsolt and Sygnature Discovery, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global In Vivo Pharmacology Service market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The In Vivo Pharmacology Service market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global In Vivo Pharmacology Service market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to In Vivo Pharmacology Service.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global In Vivo Pharmacology Service market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
In Vivo Pharmacology Service Market by Company
NuChem Sciences Inc
Eurofins Discovery
Oncodesign Services
Jubilant Biosys
Pharmaron
Melior Discovery
NUVISAN GmbH
Porsolt
Sygnature Discovery
Aurigene Pharmaceutical Services Ltd
Reaction Biology
Addexbio
Paraza Pharma, Inc
Aragen Life Sciences Ltd
Dalriada
Biocytogen
Charles River Laboratories
Pharmacelsu
HitGen Inc
TCG Lifesciences
In Vivo Pharmacology Service Segment by Type
Small Molecule Screening
Large Molecule Screening
Others
In Vivo Pharmacology Service Segment by Application
Neurological Diseases
Cardiovascular and Metabolic Diseases
Skin Diseases
Others
In Vivo Pharmacology Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global In Vivo Pharmacology Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of In Vivo Pharmacology Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of In Vivo Pharmacology Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of In Vivo Pharmacology Service companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule Screening
- Large Molecule Screening
- Others
Applications
- Neurological Diseases
- Cardiovascular and Metabolic Diseases
- Skin Diseases
- Others
Companies covered
- NuChem Sciences Inc
- Eurofins Discovery
- Oncodesign Services
- Jubilant Biosys
- Pharmaron
- Melior Discovery
- NUVISAN GmbH
- Porsolt
- Sygnature Discovery
- Aurigene Pharmaceutical Services Ltd
- Reaction Biology
- Addexbio
- Paraza Pharma, Inc
- Aragen Life Sciences Ltd
- Dalriada
- Biocytogen
- Charles River Laboratories
- Pharmacelsu
- HitGen Inc
- TCG Lifesciences
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global In Vivo Pharmacology Service Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global In Vivo Pharmacology Service Market Size by Region (2021-2032)
- 1.4.1 Global In Vivo Pharmacology Service Market Size by Region (2021-2026)
- 1.4.2 Global In Vivo Pharmacology Service Market Size by Region (2027-2032)
- 1.5 Key Regions In Vivo Pharmacology Service Market Size (2021-2032)
- 1.5.1 North America In Vivo Pharmacology Service Market Size Growth Rate (2021-2032)
- 1.5.2 Europe In Vivo Pharmacology Service Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific In Vivo Pharmacology Service Market Size Growth Rate (2021-2032)
- 1.5.4 South America In Vivo Pharmacology Service Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa In Vivo Pharmacology Service Market Size Growth Rate (2021-2032)
2 In Vivo Pharmacology Service Market by Type
- 2.1 Type Introduction
- 2.1.1 Small Molecule Screening
- 2.1.2 Large Molecule Screening
- 2.1.3 Others
- 2.2 Global In Vivo Pharmacology Service Market Size by Type
- 2.2.1 Global In Vivo Pharmacology Service Market Size Overview by Type (2021-2032)
- 2.2.2 Global In Vivo Pharmacology Service Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global In Vivo Pharmacology Service Market Size Forecasted by Type (2027-2032)
- 2.3 Global In Vivo Pharmacology Service Market Size by Regions
- 2.3.1 North America In Vivo Pharmacology Service Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe In Vivo Pharmacology Service Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific In Vivo Pharmacology Service Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America In Vivo Pharmacology Service Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa In Vivo Pharmacology Service Market Size Breakdown by Type (2021-2026)
3 In Vivo Pharmacology Service Market by Application
- 3.1 Type Introduction
- 3.1.1 Neurological Diseases
- 3.1.2 Cardiovascular and Metabolic Diseases
- 3.1.3 Skin Diseases
- 3.1.4 Others
- 3.2 Global In Vivo Pharmacology Service Market Size by Application
- 3.2.1 Global In Vivo Pharmacology Service Market Size Overview by Application (2021-2032)
- 3.2.2 Global In Vivo Pharmacology Service Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global In Vivo Pharmacology Service Market Size Forecasted by Application (2027-2032)
- 3.3 Global In Vivo Pharmacology Service Market Size by Regions
- 3.3.1 North America In Vivo Pharmacology Service Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe In Vivo Pharmacology Service Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific In Vivo Pharmacology Service Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America In Vivo Pharmacology Service Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa In Vivo Pharmacology Service Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 In Vivo Pharmacology Service Industry Trends
- 4.2 In Vivo Pharmacology Service Industry Drivers
- 4.3 In Vivo Pharmacology Service Industry Opportunities and Challenges
- 4.4 In Vivo Pharmacology Service Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by In Vivo Pharmacology Service Revenue (2021-2026)
- 5.2 Global In Vivo Pharmacology Service Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global In Vivo Pharmacology Service Key Company Headquarters & Area Served
- 5.4 Global In Vivo Pharmacology Service Company, Product Type & Application
- 5.5 Global In Vivo Pharmacology Service Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global In Vivo Pharmacology Service Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 In Vivo Pharmacology Service Players Market Share by Revenue in 2025
- 5.6.3 2025 In Vivo Pharmacology Service Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 NuChem Sciences Inc
- 6.1.1 NuChem Sciences Inc Company Information
- 6.1.2 NuChem Sciences Inc Business Overview
- 6.1.3 NuChem Sciences Inc In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 NuChem Sciences Inc In Vivo Pharmacology Service Product Portfolio
- 6.1.5 NuChem Sciences Inc Recent Developments
- 6.2 Eurofins Discovery
- 6.2.1 Eurofins Discovery Company Information
- 6.2.2 Eurofins Discovery Business Overview
- 6.2.3 Eurofins Discovery In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Eurofins Discovery In Vivo Pharmacology Service Product Portfolio
- 6.2.5 Eurofins Discovery Recent Developments
- 6.3 Oncodesign Services
- 6.3.1 Oncodesign Services Company Information
- 6.3.2 Oncodesign Services Business Overview
- 6.3.3 Oncodesign Services In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Oncodesign Services In Vivo Pharmacology Service Product Portfolio
- 6.3.5 Oncodesign Services Recent Developments
- 6.4 Jubilant Biosys
- 6.4.1 Jubilant Biosys Company Information
- 6.4.2 Jubilant Biosys Business Overview
- 6.4.3 Jubilant Biosys In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Jubilant Biosys In Vivo Pharmacology Service Product Portfolio
- 6.4.5 Jubilant Biosys Recent Developments
- 6.5 Pharmaron
- 6.5.1 Pharmaron Company Information
- 6.5.2 Pharmaron Business Overview
- 6.5.3 Pharmaron In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pharmaron In Vivo Pharmacology Service Product Portfolio
- 6.5.5 Pharmaron Recent Developments
- 6.6 Melior Discovery
- 6.6.1 Melior Discovery Company Information
- 6.6.2 Melior Discovery Business Overview
- 6.6.3 Melior Discovery In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Melior Discovery In Vivo Pharmacology Service Product Portfolio
- 6.6.5 Melior Discovery Recent Developments
- 6.7 NUVISAN GmbH
- 6.7.1 NUVISAN GmbH Company Information
- 6.7.2 NUVISAN GmbH Business Overview
- 6.7.3 NUVISAN GmbH In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 NUVISAN GmbH In Vivo Pharmacology Service Product Portfolio
- 6.7.5 NUVISAN GmbH Recent Developments
- 6.8 Porsolt
- 6.8.1 Porsolt Company Information
- 6.8.2 Porsolt Business Overview
- 6.8.3 Porsolt In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Porsolt In Vivo Pharmacology Service Product Portfolio
- 6.8.5 Porsolt Recent Developments
- 6.9 Sygnature Discovery
- 6.9.1 Sygnature Discovery Company Information
- 6.9.2 Sygnature Discovery Business Overview
- 6.9.3 Sygnature Discovery In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Sygnature Discovery In Vivo Pharmacology Service Product Portfolio
- 6.9.5 Sygnature Discovery Recent Developments
- 6.10 Aurigene Pharmaceutical Services Ltd
- 6.10.1 Aurigene Pharmaceutical Services Ltd Company Information
- 6.10.2 Aurigene Pharmaceutical Services Ltd Business Overview
- 6.10.3 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Service Product Portfolio
- 6.10.5 Aurigene Pharmaceutical Services Ltd Recent Developments
- 6.11 Reaction Biology
- 6.11.1 Reaction Biology Company Information
- 6.11.2 Reaction Biology Business Overview
- 6.11.3 Reaction Biology In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Reaction Biology In Vivo Pharmacology Service Product Portfolio
- 6.11.5 Reaction Biology Recent Developments
- 6.12 Addexbio
- 6.12.1 Addexbio Company Information
- 6.12.2 Addexbio Business Overview
- 6.12.3 Addexbio In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Addexbio In Vivo Pharmacology Service Product Portfolio
- 6.12.5 Addexbio Recent Developments
- 6.13 Paraza Pharma, Inc
- 6.13.1 Paraza Pharma, Inc Company Information
- 6.13.2 Paraza Pharma, Inc Business Overview
- 6.13.3 Paraza Pharma, Inc In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Paraza Pharma, Inc In Vivo Pharmacology Service Product Portfolio
- 6.13.5 Paraza Pharma, Inc Recent Developments
- 6.14 Aragen Life Sciences Ltd
- 6.14.1 Aragen Life Sciences Ltd Company Information
- 6.14.2 Aragen Life Sciences Ltd Business Overview
- 6.14.3 Aragen Life Sciences Ltd In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Aragen Life Sciences Ltd In Vivo Pharmacology Service Product Portfolio
- 6.14.5 Aragen Life Sciences Ltd Recent Developments
- 6.15 Dalriada
- 6.15.1 Dalriada Company Information
- 6.15.2 Dalriada Business Overview
- 6.15.3 Dalriada In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Dalriada In Vivo Pharmacology Service Product Portfolio
- 6.15.5 Dalriada Recent Developments
- 6.16 Biocytogen
- 6.16.1 Biocytogen Company Information
- 6.16.2 Biocytogen Business Overview
- 6.16.3 Biocytogen In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Biocytogen In Vivo Pharmacology Service Product Portfolio
- 6.16.5 Biocytogen Recent Developments
- 6.17 Charles River Laboratories
- 6.17.1 Charles River Laboratories Company Information
- 6.17.2 Charles River Laboratories Business Overview
- 6.17.3 Charles River Laboratories In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 Charles River Laboratories In Vivo Pharmacology Service Product Portfolio
- 6.17.5 Charles River Laboratories Recent Developments
- 6.18 Pharmacelsu
- 6.18.1 Pharmacelsu Company Information
- 6.18.2 Pharmacelsu Business Overview
- 6.18.3 Pharmacelsu In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.18.4 Pharmacelsu In Vivo Pharmacology Service Product Portfolio
- 6.18.5 Pharmacelsu Recent Developments
- 6.19 HitGen Inc
- 6.19.1 HitGen Inc Company Information
- 6.19.2 HitGen Inc Business Overview
- 6.19.3 HitGen Inc In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.19.4 HitGen Inc In Vivo Pharmacology Service Product Portfolio
- 6.19.5 HitGen Inc Recent Developments
- 6.20 TCG Lifesciences
- 6.20.1 TCG Lifesciences Company Information
- 6.20.2 TCG Lifesciences Business Overview
- 6.20.3 TCG Lifesciences In Vivo Pharmacology Service Revenue, Global Share and Gross Margin (2021-2026)
- 6.20.4 TCG Lifesciences In Vivo Pharmacology Service Product Portfolio
- 6.20.5 TCG Lifesciences Recent Developments
7 North America
- 7.1 North America In Vivo Pharmacology Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America In Vivo Pharmacology Service Market Size by Country (2021-2026)
- 7.3 North America In Vivo Pharmacology Service Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe In Vivo Pharmacology Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe In Vivo Pharmacology Service Market Size by Country (2021-2026)
- 8.3 Europe In Vivo Pharmacology Service Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific In Vivo Pharmacology Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific In Vivo Pharmacology Service Market Size by Country (2021-2026)
- 9.3 Asia-Pacific In Vivo Pharmacology Service Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America In Vivo Pharmacology Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America In Vivo Pharmacology Service Market Size by Country (2021-2026)
- 10.3 South America In Vivo Pharmacology Service Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa In Vivo Pharmacology Service Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa In Vivo Pharmacology Service Market Size by Country (2021-2026)
- 11.3 Middle East & Africa In Vivo Pharmacology Service Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst